Welcome to
Sysmex Flow Cytometry Other European Country!

For ordering please make sure you are in your local shop.
If you are from Other European Country then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD28 FITC

CyFlow™ CD28 FITC
Antigen: CD28
Alternative Name: Tp44
Clone: JJ319
Application: Flow cytometry
Format/Fluorochrome: FITC
Laser: Blue
Target Species: Rat
Field of Interest: Immunophenotyping, MHC
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG1
Order number: CM005264

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

Concentration Unit mg/mL Concentration 0.5 Quantity 0.1 mg Volume 0.2... more
CyFlow™ CD28 FITC
Concentration Unitmg/mL
Quantity0.1 mg
ImmunogenMouse A20J B lymphoma cells transfected with rat CD28
Background InformationCD28 is the critical T cell costimulatory receptor which provides to the cell the important second activation signal by binding CD80 and CD86 that are expressed by antigen presenting cells. Besides its costimulation role CD28 functions in preventing T cells from anergic hyporesponsive state or from undergoing premature apoptotic cell death. Its analog CTLA-4, expressed on the surface of activated T cells, has higher affinity to CD80 and CD86 than CD28 and downregulates T cell activity.
UsageThe reagent is designed for Flow Cytometry analysis. Working concentrations should be determined by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Tacke M, Hanke G, Hanke T, Hünig T: CD28‑mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur·J·Immunol. 1997·Jan; 27(1):239‑47. <·PMID:·9022025·> | Dengler TJ, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl CF, Hünig T, Meuer SC: Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high‑responder rat heart transplantation. Transplantation. 1999·Feb·15; 67(3):392‑8. <·PMID:·10030284·> | Robinson LE, Clandinin MT, Field CJ: R3230AC rat mammary tumor and dietary long‑chain (n‑3) fatty acids change immune cell composition and function during mitogen activation. J·Nutr. 2001·Jul; 131(7):2021‑7. <·PMID:·11435524·> | Laskowski IA, Pratschke J, Wilhelm MJ, Dong VM, Beato F, Taal M, Gasser M, Hancock WW, Sayegh MH, Tilney NL: Anti‑CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J·Am·Soc·Nephrol. 2002·Feb; 13(2):519‑27. <·PMID:·11805183·> | Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, Soulillou JP, Vanhove B: Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self‑restricted responses. Blood. 2002·Mar·15; 99(6):2228‑34. <·PMID:·11877302·> | Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, Kerkau T, Ikemizu S, Davis SJ, Hanke T, Hünig T: Topological requirements and signaling properties of T cell‑activating, anti‑CD28 antibody superagonists. J·Exp·Med. 2003·Apr·21; 197(8):955‑66. <·PMID:·12707299·> | van den Brandt J, Wang D, Reichardt HM: Resistance of single‑positive thymocytes to glucocorticoid‑induced apoptosis is mediated by CD28 signaling. Mol·Endocrinol. 2004·Mar; 18(3):687‑95. <·PMID:·14701943·> | Kerstan A, Armbruster N, Leverkus M, Hünig T: Cyclosporin A abolishes CD28‑mediated resistance to CD95‑induced apoptosis via superinduction of caspase‑3. J·Immunol. 2006·Dec·1; 177(11):7689‑97. <·PMID:·17114439·> | Guillonneau C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, Usal C, Veziers J, Anegon I, Vanhove B: Anti‑CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig‑treated heart allograft recipients. J·Immunol. 2007·Dec·15; 179(12):8164‑71. <·PMID:·18056359·>